AstraZeneca Initiates Recruitment For Two New Phase III Trials Investigating SAPHNELO In Cutaneous Lupus Erythematosus (LAVENDER) And Idiopathic Inflammatory Myopathies (JASMINE)
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca has started recruiting for two new Phase III trials to evaluate SAPHNELO in treating Cutaneous Lupus Erythematosus and Idiopathic Inflammatory Myopathies. These trials, named LAVENDER and JASMINE, aim to explore the efficacy of SAPHNELO in these conditions.
September 19, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca has initiated recruitment for two Phase III trials to test SAPHNELO in Cutaneous Lupus Erythematosus and Idiopathic Inflammatory Myopathies. Successful trials could expand SAPHNELO's market and boost AstraZeneca's revenue.
The initiation of Phase III trials is a significant step in drug development. If successful, SAPHNELO could be approved for new indications, potentially increasing AstraZeneca's market share and revenue. This news is likely to positively impact AZN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90